The hemolytic inhibition assay evaluates the effectiveness of complement inhibitors by measuring their ability to prevent red blood cell lysis. It supports research into immune regulation, complement deficiencies, and therapeutic development. By comparing hemolysis levels in treated versus untreated samples, this assay helps quantify inhibitor potency and assess complement activity across classical and alternative pathways.
